Solid Biosciences Inc. balance sheet SLDB

Annual Quarterly

As of Sep 30, 2026, Solid Biosciences Inc. had total assets of $389.9 million and total liabilities of $47.8 million. Total assets were up 42.3% from a year earlier. Stockholders' equity was $342.1 million. It held $348.9 million in cash and investments against $19.6 million of total debt, net cash of $329.3 million. The current ratio, current assets divided by current liabilities, was 11.99.

USD in millions, except ratios and per-share amounts. The percent under a figure is the change from the year before.

FY 2026
Sep 30, 2026
FY 2025
Dec 31, 2025
FY 2024
Dec 31, 2024
FY 2023
Dec 31, 2023
FY 2022
Dec 31, 2022
FY 2021
Dec 31, 2021
FY 2020
Dec 31, 2020
FY 2019
Dec 31, 2019
FY 2018
Dec 31, 2018
Assets
Cash
126
+105.3%
60
-25.3%
80
+8.4%
74
-52.4%
155
+30.4%
119
-23.0%
155
+103.5%
76
-12.0%
86
Short-term investments
223
+27.6%
128
+86.3%
69
+38.4%
50
-14.9%
58
-34.2%
89
+1084.9%
—
7
-79.3%
36
Cash and investments
349
+47.8%
188
+26.1%
149
+20.4%
124
-42.1%
214
+2.9%
208
+28.1%
155
+85.3%
84
-31.8%
122
Total current assets
365
+49.1%
205
+30.6%
157
+21.2%
130
-40.9%
220
-1.3%
223
+40.1%
159
+84.1%
86
-32.9%
129
Property and equipment, net
4
-14.3%
4
-12.2%
5
-28.3%
7
-31.4%
10
+49.4%
6
-20.7%
8
-30.0%
12
+11.7%
10
Total assets
390
+42.3%
233
+23.3%
189
+14.4%
165
-36.6%
260
+12.0%
232
+35.8%
171
+65.4%
103
-25.9%
140
Liabilities and equity
Accounts payable
3
-61.7%
3
-23.9%
4
+108.5%
2
-37.2%
3
-27.4%
4
+36.3%
3
-54.0%
7
+93.0%
4
Total current liabilities
30
-16.2%
33
+10.6%
30
+108.4%
15
-35.5%
23
-4.6%
24
-3.6%
24
+33.9%
18
+46.4%
12
Total liabilities
48
-14.6%
53
+2.2%
51
+33.7%
38
-20.8%
49
+101.0%
24
-38.2%
39
+66.9%
23
+62.5%
14
Stockholders' equity
342
+57.0%
180
+31.2%
137
+8.5%
126
-40.2%
212
+1.7%
208
+57.6%
132
+65.0%
80
—
Debt
Lease liabilities
20
-10.5%
21
-12.5%
24
-7.9%
26
+0.3%
26
+1168.8%
2
-59.9%
5
-27.1%
7
—
Total debt
20
-10.5%
21
-12.5%
24
-7.9%
26
+0.3%
26
+1168.8%
2
-59.9%
5
-27.1%
7
—
Net cash
329
+53.7%
167
+33.6%
125
+28.1%
97
-48.1%
188
-8.8%
206
+31.0%
150
+95.7%
76
—
Ratios
Current ratio
11.99x
6.14x
5.20x
8.94x
9.76x
9.43x
6.49x
4.72x
10.31x
Debt to equity
0.06x
0.12x
0.18x
0.21x
0.12x
0.01x
0.04x
0.09x
—
Return on equity
-62.92%
-96.84%
-90.86%
-75.91%
-40.62%
-34.67%
-66.84%
-146.44%
—
Return on assets
-55.21%
-74.97%
-66.10%
-58.21%
-33.04%
-31.06%
-51.58%
-113.29%
-53.58%
Book value per share
3.07
2.28
3.39
6.20
10.82
28.30
1.56
1.74
—
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except ratios and per-share amounts. Cash and investments adds short-term and long-term marketable securities to cash. Debt due within a year is the borrowings that are not already in long-term debt. Total debt is those borrowings plus lease liabilities. Net cash is cash and investments minus total debt. Return on equity and return on assets divide the trailing twelve months of net income by the balance on that date. Debt to EBITDA uses the trailing twelve months of EBITDA. The first column is the latest balance sheet when it is newer than the latest fiscal year. More on our methodology.

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
SLDB (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Charlestown, MA
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1707502
Former names
Solid Biosciences, LLC (until Jan 25, 2018)

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.